Theravance & Mylan v. Eugia, CIPLA & Aurobindo: YUPELRI® Patent Consolidated
Theravance Biopharma and Mylan filed a Hatch-Waxman infringement action in New Jersey against Eugia, CIPLA, Aurobindo, and Mankind Pharma over US12048692B2 — a newly granted patent covering YUPELRI® (revefenacin) inhalation solution. The case closed after just 57 days when it was consolidated into a broader 11-patent lead action already before the same court.
Orange Book race: a new YUPELRI® patent triggers a third NJ ANDA action
On August 19, 2024, Theravance Biopharma R&D IP LLC, Theravance Biopharma US Inc., Theravance Biopharma Ireland Limited, Mylan Ireland Limited, and Mylan Specialty LP filed case 1:24-cv-08558 in the District of New Jersey against Eugia Pharma Specialities, Eugia US LLC, CIPLA Limited, CIPLA USA Inc., Aurobindo Pharma Limited, Aurobindo Pharma USA Inc., Mankind Pharma Ltd., and Lifestar Pharma LLC. The sole patent asserted was US12048692B2, granted on July 30, 2024 and immediately listed in the Orange Book against YUPELRI® (revefenacin) inhalation solution.
The case closed on October 15, 2024 — 57 days after filing — pursuant to a consolidation order directing that the 8558 Action be administratively terminated and merged into lead case 1:23-cv-00926. No merits ruling, claim construction, or damages determination was issued. The ‘692 patent joins ten other patents already in suit in the lead action, which itself absorbed a prior related action (1:24-cv-00150) covering US11858898.
The 57-day closure reflects standard Hatch-Waxman case management rather than any substantive weakness in either side’s position. Plaintiffs filed promptly upon grant of the ‘692 patent to preserve the 30-month stay mechanism under the Drug Price Competition and Patent Term Restoration Act. All substantive patent validity, enforceability, and infringement questions — including for the ‘692 patent — remain live in the consolidated lead case, whose schedule is being amended to incorporate the additional patent.
Filing to Case Consolidated in 57 days
57 days — well below the median ANDA case lifespan; closed by consolidation order, not merits adjudication
Administrative consolidation: what closing this case actually means
Consolidation ≠ dismissal — the dispute lives on
Under Fed. R. Civ. P. 42(a), courts may consolidate actions sharing common questions of law or fact. Here, all parties agreed consolidation would conserve judicial resources. The 8558 Action was administratively terminated — not dismissed on the merits — and its sole patent, US12048692B2, is now litigated within lead case 1:23-cv-00926. No rights were waived; no claims resolved.
No merits adjudicationFiling on grant preserves the 30-month ANDA stay
Theravance and Mylan filed this action within days of the ‘692 patent issuing, consistent with the Hatch-Waxman obligation to sue within 45 days of receiving a Paragraph IV certification to trigger a 30-month FDA approval stay. Consolidation into the lead case likely aligns the ‘692 patent’s trial schedule with the broader portfolio, maximising enforcement efficiency without sacrificing stay rights.
30-month stay preservedSeven generic filers now face an 11-patent consolidated action
Eugia, CIPLA, Aurobindo, Mankind, and associated US entities collectively face 11 Orange Book-listed patents in the consolidated proceedings. The addition of US12048692B2 — related to US11484531 already in suit — suggests layered continuation coverage around YUPELRI®. Invalidity and non-infringement arguments must now address the full patent family, raising the cost and complexity of the generic defence.
Expanded patent exposureYUPELRI® market exclusivity window remains heavily contested
YUPELRI® (revefenacin) is the first once-daily, nebulised bronchodilator approved for COPD maintenance. With 11 patents now in suit — spanning compound, formulation, and method claims — generic entry faces a complex litigation gauntlet. The consolidation order streamlines proceedings but does not shorten the substantive timeline; a consolidated trial on all patents may extend market exclusivity well beyond individual patent expiry dates.
Generic entry delayedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Theravance Biopharma R & D IP, LLC | Company | Biopharmaceutical IP and commercialisation entities — holders of US12048692B2 covering YUPELRI®Search in Eureka ↗ |
| Co-Plaintiff | Mylan Ireland Limited | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Theravance Biopharma Ireland Limited | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Theravance Biopharma US, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Mylan Specialty, LP | Company | Search in Eureka ↗ |
| Defendant | Eugia Pharma Specialities, Ltd. | Company | Generic pharmaceutical manufacturers seeking ANDA approval for revefenacin inhalation solutionSearch in Eureka ↗ |
| Co-Defendant | Eugia US LLC | Company | Search in Eureka ↗ |
| Co-Defendant | CIPLA Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | CIPLA USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma Limited, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Mankind Pharma, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Lifestar Pharma LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Arnold B. Calmann | Attorney | Counsel for Theravance Biopharma R & D IP, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Katherine Ann Escanlar | Attorney | Counsel for Theravance Biopharma R & D IP, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Saiber LLC | Law Firm | Representing Theravance Biopharma R & D IP, LLCSearch in Eureka ↗ |
| Defendant counsel | R. Touhey Myer | Attorney | Counsel for Eugia Pharma Specialities, Ltd.Search in Eureka ↗ |
| Defendant law firm | Kratz & Barry, LLP | Law Firm | Representing Eugia Pharma Specialities, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order is procedural, not substantive. The court found that the 8558 Action and the lead 926 Action share common parties, patents, and factual questions sufficient to warrant merger under Rule 42(a). The order does not resolve infringement, validity, or enforceability of US12048692B2. All claims are preserved and will be adjudicated in the consolidated proceedings under lead case 1:23-cv-00926, with an amended scheduling order to follow. The administrative termination of the 8558 docket is a housekeeping measure only.
US12048692B2 — YUPELRI® (revefenacin) inhalation solution
US12048692B2 was granted on July 30, 2024 and immediately listed in the FDA Orange Book against YUPELRI® (revefenacin) inhalation solution. The patent is related to US11484531, one of ten other patents already in suit, suggesting it issues from the same continuation family and likely covers overlapping compound, formulation, or method-of-treatment claims directed at once-daily nebulised revefenacin — the first long-acting muscarinic antagonist approved in that delivery form for COPD maintenance. The rapid Orange Book listing and immediate assertion against pending ANDAs reflects a deliberate lifecycle management strategy.
For the COPD inhalation therapy sector, a freshly granted patent entering active litigation is a significant competitive signal. The ‘692 patent extends the potential enforcement timeline for YUPELRI® and, if upheld, could delay generic nebulised revefenacin entry. Competitors and generic developers should note that the full Theravance/Mylan portfolio now encompasses 11 Orange Book patents across multiple patent families — a coverage density that materially increases the risk and cost of challenging market exclusivity through the ANDA pathway.
Should you run an FTO against US12048692B2?
Any company developing, manufacturing, or planning to commercialise a nebulised long-acting muscarinic antagonist (LAMA) for COPD — or formulating revefenacin or structurally related compounds — should treat US12048692B2 as a priority FTO target. The patent is actively asserted, Orange Book-listed, and related to a family of 11 patents spanning compound, formulation, and use claims. An FTO gap here could expose a product to a 30-month ANDA stay before FDA approval is even granted.
PatSnap Eureka’s FTO Search Agent can map US12048692B2 against your specific compound or formulation claims, identify related continuation and divisional applications still pending prosecution, and flag claim language overlap with your product pipeline. Given the multi-patent family structure here, a full family-level FTO — not just a single-patent review — is strongly advisable before any ANDA or 505(b)(2) filing directed at YUPELRI® or revefenacin-class products.
Run a freedom-to-operate analysis on US12048692B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: COPD inhalation therapy litigation in NJ
Explore comparable Hatch-Waxman ANDA infringement cases involving inhalation therapy and respiratory drug patents litigated in the District of New Jersey.
What this case signals for the COPD inhalation therapy IP landscape
The rapid Orange Book listing and immediate litigation of US12048692B2 illustrates a well-executed patent evergreening playbook in the respiratory pharma sector.
File fast on new Orange Book patents — the 45-day window is unforgiving
Theravance and Mylan filed this action within 20 days of US12048692B2 issuing, well inside the 45-day Hatch-Waxman window. Missing that window forfeits the automatic 30-month FDA approval stay — a critical exclusivity tool. Any branded pharmaceutical company with ANDA challengers must monitor patent grant dates in real time and have litigation counsel pre-positioned to file.
Consolidation strategy can simplify multi-front ANDA defence
With three separate actions now merged into one lead case, both sides benefit from a single discovery track and coordinated trial. For generic defendants, consolidation can reduce duplicative costs but also means every invalidity argument must survive scrutiny across all asserted patents simultaneously — raising the stakes of each motion.
Theravance v Eugia — key questions answered
Case 1:24-cv-08558 was a Hatch-Waxman patent infringement action filed August 19, 2024 asserting US12048692B2 against Eugia, CIPLA, Aurobindo, and Mankind Pharma over YUPELRI® generic ANDAs. The case closed October 15, 2024 — 57 days later — when it was consolidated into lead case 1:23-cv-00926 by court order. No merits ruling was issued.
US12048692B2 is a patent granted July 30, 2024 covering aspects of revefenacin (YUPELRI®) inhalation solution for COPD. It is related to US11484531, one of ten other patents in the consolidated lead case. It was asserted because the Hatch-Waxman framework allows patentees to sue ANDA filers within 45 days of a Paragraph IV certification to trigger a 30-month FDA approval stay.
Consolidation means Eugia, CIPLA, Aurobindo, Mankind, and their US affiliates now face all 11 Orange Book patents — including US12048692B2 — in a single proceeding under lead case 1:23-cv-00926. Discovery, case management, and trial are unified. No claims were dismissed; generic entry to the revefenacin market remains blocked pending resolution of the consolidated action.
No. Administrative termination is a docket management measure. The ‘692 patent (US12048692B2) and all related infringement allegations were expressly preserved and transferred into lead case 1:23-cv-00926. The court order confirms all filings must proceed under the lead case caption going forward.
Under the Hatch-Waxman Act, if a branded drug patentee sues an ANDA filer within 45 days of receiving a Paragraph IV certification, the FDA cannot approve the generic for 30 months. By filing promptly upon grant of US12048692B2, Theravance and Mylan preserved this stay right for the ‘692 patent, extending the period during which FDA approval of generic YUPELRI® is automatically withheld.
PatSnap Eureka searches patents and litigation data to answer instantly.